[Activity of ticlopidine and lysine acetylsalicylate in experimental atheromatosis. Effects on the production of PGI2].
D015121:6-Ketoprostaglandin F1 alpha / Q000096:biosynthesis; D000818:Animals; D001011:Aorta / Q000378:metabolism; D001161:Arteriosclerosis / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D001241:Aspirin / Q000031:analogs & derivatives* / Q000494:pharmacology; D004036:Diet, Atherogenic; D011464:Epoprostenol / Q000096:biosynthesis*; D008239:Lysine / Q000031:analogs & derivatives* / Q000494:pharmacology; D008297:Male; D010974:Platelet Aggregation / Q000187:drug effects; D011817:Rabbits; D013876:Thiophenes / Q000494:pharmacology*; D013988:Ticlopidine
D013876:Thiophenes; D015121:6-Ketoprostaglandin F1 alpha; D011464:Epoprostenol; D008239:Lysine; D013988:Ticlopidine; D001241:Aspirin; C010395:acetylsalicylic acid lysinate
Acción de la ticlopidina y del acetil salicilato de lisina en la ateromatosis experimental. Efectos en la producción de PGI2.